Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Haemonetics (HAE) over the last 13 years, with Q4 2025 value amounting to $11.6 million.

  • Haemonetics' Other Operating Expenses fell 475.06% to $11.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $31.1 million, marking a year-over-year decrease of 4659.62%. This contributed to the annual value of $2.0 million for FY2024, which is 42356.02% up from last year.
  • Haemonetics' Other Operating Expenses amounted to $11.6 million in Q4 2025, which was down 475.06% from $19.8 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Other Operating Expenses registered a high of $19.8 million during Q3 2025, and its lowest value of -$11.7 million during Q1 2025.
  • Over the past 5 years, Haemonetics' median Other Operating Expenses value was $10.5 million (recorded in 2021), while the average stood at $8.6 million.
  • In the last 5 years, Haemonetics' Other Operating Expenses surged by 179057.59% in 2023 and then crashed by 16222.67% in 2025.
  • Over the past 5 years, Haemonetics' Other Operating Expenses (Quarter) stood at $9.6 million in 2021, then crashed by 96.02% to $382000.0 in 2022, then surged by 1709.16% to $6.9 million in 2023, then surged by 76.96% to $12.2 million in 2024, then decreased by 4.75% to $11.6 million in 2025.
  • Its Other Operating Expenses stands at $11.6 million for Q4 2025, versus $19.8 million for Q3 2025 and $11.4 million for Q2 2025.